)
Edge12 Dec 2025
Running on Clouds: The Story of On
The story of how a Swiss runner's pursuit of a new running sensation became On, aiming to be the most premium global sportswear brand worldwide.
BridgeBio Pharma
BridgeBio Pharma (BBIO) investor relations material
BridgeBio Pharma 44th Annual J.P. Morgan Healthcare Conference summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.44th Annual J.P. Morgan Healthcare Conference summary12 Jan, 2026
Strategic vision and leadership
Focus on becoming a fully integrated biopharma company, advancing from discovery to commercialization.
Deep expertise in CNS ion channel drug development underpins the portfolio strategy.
Major emphasis on azetukalner, with expansion into psychiatry and early-stage pipeline development.
Recent hires in commercial and financial leadership to support forward integration.
Commitment to building a world-class team with deep epilepsy experience for launch success.
Clinical pipeline and trial updates
Six ongoing phase III trials for azetukalner: three in epilepsy, three in neuropsychiatry.
X-TOLE2 phase III in focal onset seizures completed randomization; top-line data expected March 2024.
X-TOLE3 includes Japanese subjects, streamlining global regulatory strategy.
Phase III trial in primary generalized tonic-clonic seizures running in parallel.
Early-stage pipeline includes Nav1.7 and Kv7 programs, with Nav1.7 showing promising phase I data.
Azetukalner efficacy and safety data
Phase II-B X-TOLE study showed best-in-class seizure reduction in a highly refractory population.
Rapid onset of efficacy observed, with significant seizure reduction within the first week.
Long-term open-label extension data show over 90% reduction in seizure burden and sustained seizure freedom for many.
Safety profile consistent with other CNS-active drugs; no new adverse events in long-term use.
High physician anticipation due to novel mechanism, ease of use, and lack of titration or drug-drug interactions.
Depleter program's clinical differentiation
Encaleret's CHP market expansion strategy
PORT-77's best-in-disease profile validation
Attruby's $1B+ 2026 revenue target. How?
LGMD2I & ADH1 "therapeutic cure" basis
EPP PORT-77's best-in-class potential. Why?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next BridgeBio Pharma earnings date
Q4 202520 Feb, 2026
BridgeBio Pharma
Next BridgeBio Pharma earnings date
Q4 202520 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company's lead candidates for the treatment of Fabry disease comprise a pipeline of recombinant enzyme-replacement therapies comprising elaprase and lysosomal-phospholipid-glycoprotein (PLG) analogs. It focuses on developing therapeutics for treating Fabry disease, a rare genetic disorder characterized by progressive loss of kidney function and the buildup of fatty substances that damage blood vessels and organs. BridgeBio Pharma, Inc.i s based in Waltham, Massachusetts.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage